Castle Biosciences CEO Derek Maetzold reports disposal of common shares valued at $791,790.26

Reuters2026/08/04 20:37

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Castle Biosciences President and CEO Derek J. Maetzold reported option exercises, acquiring 17,144 common shares at USD 2.39 on July 31 and Aug. 3.
He sold 17,144 shares at weighted-average prices of about USD 30.15 and USD 30.35 on the same dates.
Maetzold’s direct common-share holdings ended at 21,479 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-052647), on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Castle Biosciences CEO Derek Maetzold reports disposal of common shares valued at $791,790.26

You may also like

Crypto prices